GSK2879552 / GSK  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK2879552 / GSK
NCT02929498 / 2016-002294-35: Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Terminated
1/2
7
US, Europe
GSK2879552, Azacitidine
GlaxoSmithKline, Parexel
Myelodysplastic Syndrome, Myelodysplastic Syndromes
01/18
01/18

Download Options